Day: June 9, 2020

AS LHV Group teenis 2020. aasta mais 2,8 miljonit eurot puhaskasumit. AS LHV Pank teenis 2,6 miljonit eurot ja AS LHV Varahaldus 0,3 miljonit eurot puhaskasumit.Eriolukorrast tingituna heitliku aprilli järel iseloomustas maikuud LHV jaoks ärimahtude taastumine ning mitme olulise projektiga lõpusirgele jõudmine. Suurenemas on nii laenuportfell, hoiuste maht kui ka fondide maht. Ettevõtete panganduse laenuportfell kasvas 12 miljoni euro ja jaelaenude portfell 10 miljoni euro võrra. Konsolideeritud hoiused kasvasid kuuga 159 miljoni euro võrra, sh maksevahendajate hoiused 116 miljoni euro võrra ja eraisikute hoiused 17 miljoni euro võrra.Muidu tavapäraste tulude ja kuludega kuu tulemusi mõjutas ka erakorralisest panga likviidsuportfelli ümberhindlusest tekkinud 0,3 miljoni euro suurune finantskulu. Tänu väiksematele allahindlustele 2,8 miljoni...

Paris, Amsterdam, June 9, 2020           Press releaseUnibail-Rodamco-Westfield scores “B” and stands out as industry leader for its ESG practices in ISS 2020 ratingUnibail-Rodamco-Westfield (URW) is once again recognized as a global leader on Environmental, Social and Corporate Governance (ESG), achieving a score of “B” from ISS (Institutional Shareholder Services group of companies) for its ESG practices in June 2020. This is an exceptional rating level among the real estate industry companies assessed worldwide, and the best grade ever for the Group. URW ranks in the leaders group (1st decile) and is, like in 2019, awarded the Prime status, which highlights its best-in-class approach.For the Group, this top grade is an achievement highlighting the relevance and strength of both its governance and its CSR Strategy, and a recognition...

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 6,181,562 shares of its common stock at a public offering price of $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 927,234 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $164.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding...

Please find attached the 2020 version of the Salmon Industry Handbook. The handbook is also available on our website www.mowi.com.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.Attachment2020 Salmon Industry Handbook

BOSTON, June 08, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share. In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 1,521,738 shares of its common stock at a purchase price of $22.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $100 million, before deducting the underwriting discounts...

CALGARY, Alberta, June 08, 2020 (GLOBE NEWSWIRE) — Cequence Energy Ltd. (“Cequence” or the “Company”) (TSX: CQE) announces that it has obtained an order form the Court of Queen’s Bench of Alberta (the “Court”) extending the stay of proceedings previously granted by the Court on May 29, 2020 as part of Cequence’s application under the Companies’ Creditors Arrangement Act (“CCAA”). The stay of proceedings has been extended  to September 8, 2020.The extension of the stay period will allow the Company to pursue potential strategic options and alternatives to maximize the value for its stakeholders. The Company intends to work toward developing a plan of compromise or arrangement under the CCAA to be voted on by its creditors.In addition to the Court order extending the stay period, the Company also sought and...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESCINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) — Protech Home Medical Corp. (the “Company”) (TSXV: PTQ) (OTCQX: PTQQF) is pleased to announce that it has filed the preliminary prospectus in connection with its previously announced bought deal public offering (the “Public Offering”) of units (“Units”) of the Company. In addition, the Company announces that it anticipates completing, concurrent with the Public Offering: (i) a brokered private placement of 1,750,000 Units (the “Brokered Private Placement”) conducted by a syndicate of agents (the “Agents”) led by Beacon Securities Limited (“Beacon”), as sole bookrunner, and Canaccord Genuity Corp., and (ii) a non-brokered private placement of 927,826 Units (the “Non-Brokered Private Placement”,...

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) — Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin. The gross proceeds from the offering are expected to be approximately $100.8 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on June 11, 2020, subject to customary closing conditions. In addition, Retrophin has granted the underwriters for the offering a 30-day option to purchase up to an additional 975,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.Jefferies, Barclays and BofA Securities are acting as the joint book-running managers...

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an underwritten public offering of 7,590,909 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock is $5.50 and the public offering price of each pre-funded warrant is $5.499 per underlying share. In addition, Kezar has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock. The offering is expected to close on June 11,...

MELBOURNE, Australia, June 08, 2020 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2a clinical trial evaluating the safety and efficacy of OPT-302 administered in combination with Eylea® (aflibercept) for treatment of persistent diabetic macular edema (DME). We welcome participation from interested parties.To access the call pre-register (preferred option) or dial-in direct (delays possible):About Opthea LimitedOpthea (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around VEGF-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. Opthea’s product development programs are focused...